Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

@article{Kurtz2011OvarianCI,
  title={Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.},
  author={John E. Kurtz and Marie Christine Kaminsky and Anne B. Floquet and Anne Sophie Veillard and Rainer Kimmig and Anne Dorum and Lorraine Elit and Martin Paul Buck and Edgar Petru and Nicolas Robert Reed and Giovanni Scambia and Nenzi Varsellona and Carl Richards Brown and E Pujade-Lauraine},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 11},
  pages={
          2417-23
        }
}
BACKGROUND CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients ≥70 years. PATIENTS AND METHODS Nine hundred and seventy-six patients with taxane-pretreated ROC relapsing >6 months after first- or second-line platinum-based therapy were randomly assigned to 4-weekly C area under the curve (AUC) 5 plus… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Ovarian cancer in the older woman.

  • Journal of geriatric oncology
  • 2016

Recurrent ovarian cancer.

E Pujade-Lauraine, Pierre Combe
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Similar Papers

Loading similar papers…